<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028782</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02438</org_study_id>
    <secondary_id>UPCC# 05901</secondary_id>
    <secondary_id>P01CA087971</secondary_id>
    <secondary_id>CDR0000069134</secondary_id>
    <nct_id>NCT00028782</nct_id>
  </id_info>
  <brief_title>EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer</brief_title>
  <official_title>The Detection of Tumor Hypoxia and Vascularity in Patients Undergoing Intraperitoneal Photodynamic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well EF5 works in detecting oxygen level and blood&#xD;
      vessels in tumor cells of patients who are undergoing photodynamic therapy for&#xD;
      intraperitoneal or pleural cancer. Diagnostic procedures using EF5 to detect oxygen level and&#xD;
      blood vessels in tumor cells may help to improve the way photodynamic therapy is given&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the level of hypoxia through etanidazole derivative EF5 binding in patients with&#xD;
      intraperitoneal or pleural malignancies treated with photodynamic therapy.&#xD;
&#xD;
      II. Determine the microvascular density in this patient population. III. Determine the&#xD;
      relationships between levels of hypoxia, measures of microvascular density, and&#xD;
      photosensitizer levels in this patient population.&#xD;
&#xD;
      IV. Correlate hypoxia and photosensitizer levels with clinical outcome in this patient&#xD;
      population.&#xD;
&#xD;
      V. Determine the toxic effects of EF5 in this patient population.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive etanidazole derivative EF5 IV over 1-2 hours. Approximately 48 hours after&#xD;
      EF5 administration, patients with intraperitoneal tumors undergo surgical resection. Patients&#xD;
      with pleural tumors undergo surgical resection approximately 24 hours after EF5&#xD;
      administration. Tumors are then analyzed for EF5 binding and microvascular density by&#xD;
      immunohistochemistry and fluorescent antibody techniques.&#xD;
&#xD;
      Patients are followed at 2 weeks and at 30-45 days post EF5 infusion.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients (50 with intraperitoneal malignancy and 30 with&#xD;
      pleural malignancy) will be accrued for this study within 2.5 years. Patients are stratified&#xD;
      by disease (intraperitoneal malignancy vs pleural malignancy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>October 2001</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of hypoxia in tumor nodules</measure>
    <time_frame>At the completion of surgery</time_frame>
    <description>Exploratory techniques will be used to describe patterns of EF5 binding as well as MVD within and among patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inter- and intra-patient variability of hypoxia by EF5 binding</measure>
    <time_frame>At the completion of surgery</time_frame>
    <description>Inter- and intra-subject variability can be estimated using summary statistics (standard deviations, or the range of data).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of microvascular density by PECAM/CD31 staining</measure>
    <time_frame>At the completion of surgery</time_frame>
    <description>Distributions of the four EF5 binding variables and MVD will be examined graphically we anticipate that certain variables may have a Poisson distribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationships among levels of hypoxia, microvascular density, and photosensitizer levels</measure>
    <time_frame>At the completion of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Associations between hypoxia and photosensitizer levels in tumor nodules with clinical outcome periodically until disease recurrence</measure>
    <time_frame>Not Provided</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of EF5 administration</measure>
    <time_frame>Up to 45 days after EF5 infusion</time_frame>
    <description>All observed toxicities will be graded, tabled for each stratum (IP study) and for the entire study and summarized by frequencies and percentages.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Advanced Malignant Mesothelioma</condition>
  <condition>Localized Malignant Mesothelioma</condition>
  <condition>Malignant Ascites</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <condition>Recurrent Malignant Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (etanidazole)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive etanidazole derivative EF5 IV over 1-2 hours. Approximately 48 hours after EF5 administration, patients with intraperitoneal tumors undergo surgical resection. Patients with pleural tumors undergo surgical resection approximately 24 hours after EF5 administration. Tumors are then analyzed for EF5 binding and microvascular density by immunohistochemistry and fluorescent antibody techniques.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanidazole</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (etanidazole)</arm_group_label>
    <other_name>2-nitro-imidazole derivative</other_name>
    <other_name>SR-2508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Diagnostic (etanidazole)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (etanidazole)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed intraperitoneal or pleural malignancy&#xD;
&#xD;
          -  Currently enrolled on 1 of 3 photodynamic therapy trials (UPCC-2997, UPCC-4997, or&#xD;
             UPCC-05503)&#xD;
&#xD;
               -  Plan to undergo surgery for treatment on one of these protocols&#xD;
&#xD;
          -  Patients with suspected recurrent disease undergoing surgery for diagnosis and&#xD;
             debulking allowed if frozen section shows malignant disease&#xD;
&#xD;
          -  No active extra-abdominal metastatic disease and/or intrahepatic involvement secondary&#xD;
             to metastatic carcinoma&#xD;
&#xD;
          -  No borderline tumors of low malignant potential&#xD;
&#xD;
          -  No abdominal disease that cannot be debulked to less than 5 mm residual disease in&#xD;
             maximal dimension&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  No severe liver disease&#xD;
&#xD;
          -  No cirrhosis&#xD;
&#xD;
          -  No grade III or IV elevations in liver function studies&#xD;
&#xD;
          -  Creatinine no greater than upper limit of normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Weight no more than 130 kg&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Able to tolerate anesthesia or major surgery&#xD;
&#xD;
          -  No grade III or IV peripheral neuropathy&#xD;
&#xD;
          -  No regional enteritis or ulcerative colitis&#xD;
&#xD;
          -  No contraindication for anesthesia or major surgery&#xD;
&#xD;
          -  Prior combination chemotherapy for malignancy allowed&#xD;
&#xD;
          -  No concurrent chemotherapy except for recurrent or persistent disease&#xD;
&#xD;
          -  No concurrent radiotherapy except for recurrent or persistent disease&#xD;
&#xD;
          -  Prior surgery for malignancy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Michael Hahn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanidazole</mesh_term>
    <mesh_term>Imidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

